Search Result

Results for "

BP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Androgen Receptor (1) Antibiotic (1) Apoptosis (10) ATM/ATR (1) Autophagy (16) Bacterial (6) Biochemical Assay Reagents (4) Calcium Channel (14) Casein Kinase (1) CDK (1) CRFR (3) DNA/RNA Synthesis (1) Dopamine Receptor (2) Endogenous Metabolite (1) FAP (1) Fluorescent Dye (5) Hexokinase (1) HSP (1) HSV (1) IFNAR (1) Insulin Receptor (2) Integrin (4) Interleukin Related (2) Isotope-Labeled Compounds (5) Liposome (17) Mitophagy (2) mTOR (3) nAChR (1) Organoid (2) p38 MAPK (2) p97 (1) PCSK9 (1) PDGFR (1) Pim (1) PROTACs (1) Pyroptosis (1) Small Interfering RNA (siRNA) (37) Sodium Channel (7) STAT (2) STING (3) VEGFR (2)
By Research Areas:	Cancer (66) Cardiovascular Disease (18) Endocrinology (1) Infection (5) Inflammation/Immunology (9) Metabolic Disease (9) Neurological Disease (14)
Click Chemistry:	Labeling and Fluorescence Imaging (1) Alkynes (1)

137

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

MCE Kits

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-100493

BP-1-102

5 Publications Verification

STAT Cancer

BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC₅₀ of 6.8 μM.

BP-1-102 5 Publications Verification	STAT	Cancer
BP-1-102 is an orally available, small-molecule inhibitor of transcription factor Stat3, with an IC₅₀ of 6.8 μM.

HY-106660

BP 897 hydrochloride	Dopamine Receptor	Neurological Disease
BP 897 hydrochloride is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 hydrochloride displays a high affinity at the dopamine D3 receptor (K_i=0.92 nM) and a 70 times lower affinity at the D2 receptor (K_i=61 nM) .

HY-114085

BP 897	Dopamine Receptor	Neurological Disease
BP 897 is a potent and partial dopamine D3 receptor agonist and a weak D2 receptor antagonist. BP 897 displays a high affinity at the dopamine D3 receptor (K_i=0.92 nM) and a 70 times lower affinity at the D2 receptor (K_i=61 nM) .

HY-W440779

BP Lipid 135

Liposome Metabolic Disease

BP Lipid 135 is a cationieally ionizable lipid. BP Lipid 135 can be used to prepare lipid nanoparticles (LNP) (WO2022218503A1) .

BP Lipid 135	Liposome	Metabolic Disease
BP Lipid 135 is a cationieally ionizable lipid. BP Lipid 135 can be used to prepare lipid nanoparticles (LNP) (WO2022218503A1) .

HY-157850

BP-M345	Others	Cancer
BP-M345 (compound 5) is a potent, cancer cell-targeting antiproliferative agent that exhibits low toxicity to non-tumor cells. BP-M345 inhibits cancer cell proliferation with a GI₅₀ value ranging from 0.17 to 0.45 μM .

HY-W440753

BP Lipid 114

Liposome Others

BP Lipid 114 is an ethanolamine ionizable lipid (CN113387825A) .

BP Lipid 114	Liposome	Others
BP Lipid 114 is an ethanolamine ionizable lipid (CN113387825A) .

HY-158862

BP Lipid 376	Liposome	Others
BP Lipid 376 features a unique piperidine ionizable head group with a carbamate linkage to the lipid scaffold comprised of a linoleate ester and aliphatic acetal ester. This lipid may be used in the development of lipid nanoparticles for drug delivery.

HY-W440752

BP Lipid 113	Liposome	Cancer
BP Lipid 113 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W800749

BP Lipid 223	Liposome	Cancer
BP Lipid 223 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W440748

BP Lipid 109	Liposome	Cancer
BP Lipid 109 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W800737

BP Lipid 126	Liposome	Cancer
BP Lipid 126 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W440743

BP Lipid 103	Liposome	Cancer
BP Lipid 103 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W440751

BP Lipid 112	Liposome	Cancer
BP Lipid 112 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W440803

BP Lipid 218	Liposome	Cancer
BP Lipid 218 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W440800

BP Lipid 226	Liposome	Cancer
BP Lipid 226 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W440766

BP Lipid 209	Liposome	Cancer
BP Lipid 209 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W800802

BP Lipid 227	Liposome	Cancer
BP Lipid 227 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W800812

BP Lipid 308	Liposome	Cancer
BP Lipid 308 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W800827

BP Lipid 229	Liposome	Cancer
BP Lipid 229 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W800841

BP Lipid 314	Liposome	Cancer
BP Lipid 314 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-W800849

BP Lipid 315	Liposome	Cancer
BP Lipid 315 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-153495

Prexigebersen

BP1001
Others Cancer

Prexigebersen is an antisense oligonucleotide designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2).

Prexigebersen BP1001	Others	Cancer
Prexigebersen is an antisense oligonucleotide designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2).

HY-153495A

Prexigebersen sodium BP1001 sodium	Others	Cancer
Prexigebersen sodium is an antisense oligonucleotide designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2).

HY-19470

Topilutamide

1 Publications Verification

BP766; Fluridil
Androgen Receptor Cancer

Topilutamide is a topical nonsteroidal antiandrogen (NSAA).

Topilutamide 1 Publications Verification BP766; Fluridil	Androgen Receptor	Cancer
Topilutamide is a topical nonsteroidal antiandrogen (NSAA).

HY-N0848

Epibrassinolide 10+ Cited Publications 24-Epibrassinolide; B1105; BP55	Apoptosis	Cancer
Epibrassinolide (24-Epibrassinolide) is a ubiquitously occurring plant growth hormone which shows great potential to alleviate heavy metals and pesticide stress in plants . Epibrassinolide is a potential apoptotic inducer in various cancer cells without affecting the non-tumor cell growth .

HY-P10131

3BP-3940	FAP	Cancer
3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment .

HY-156110

IGF2BP1-IN-1	Insulin Receptor	Cancer
IGF2BP1-IN-1 (Compound A11) is a *IGF2BP1* inhibitor and inhibits downstream signaling. IGF2BP1-IN-1 binds to IGF2BP1 protein with a K_D value of 2.88 nM. IGF2BP1-IN-1 inhibits cancer cells proliferation (IC₅₀: 9 nM for A549 cell, 34 nM for HCT116). IGF2BP1-IN-1 induces cancer cell apoptosis. GF2BP1-IN-1 inhibits tumor growth in A549 xenograft mouse model .

HY-D1418

CP-BP-SFAC

Fluorescent Dye Others

CP-BP-SFAC is a luminogenic molecule. CP-BP-SFAC exhibits strong sky-blue delayed fluorescence in neat films .

CP-BP-SFAC	Fluorescent Dye	Others
CP-BP-SFAC is a luminogenic molecule. CP-BP-SFAC exhibits strong sky-blue delayed fluorescence in neat films .

HY-D1417

P-BP-SFAC	Fluorescent Dye	Others
P-BP-SFAC is a fluorescence molecule. P-BP-SFAC exhibits an apparent absorption band with a peak at about 377 nm, indicative of a stronger ICT effect .

HY-P6010

αvβ6-BP

Integrin Cancer

αvβ6-BP is a selective αvβ6 binding peptide, and can be used for molecular imaging .
HY-110087

4BP-TQS

nAChR Neurological Disease

4BP-TQS is a potent allosteric agonist of α7 nAChR. 4BP-TQS activates nAChRs via an allosteric transmembrane site .
HY-P6009

Cys-αvβ6-BP

Integrin Cancer

Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide .
HY-P6010A

αvβ6-BP TFA

Integrin Cancer

αvβ6-BP TFA is a selective αvβ6 binding peptide, and can be used for research of molecular imaging .

αvβ6-BP	Integrin	Cancer
αvβ6-BP is a selective αvβ6 binding peptide, and can be used for molecular imaging .

4BP-TQS	nAChR	Neurological Disease
4BP-TQS is a potent allosteric agonist of α7 nAChR. 4BP-TQS activates nAChRs via an allosteric transmembrane site .

Cys-αvβ6-BP	Integrin	Cancer
Cys-αvβ6-BP is a cysteine-terminated αvβ6 binding peptide .

αvβ6-BP TFA	Integrin	Cancer
αvβ6-BP TFA is a selective αvβ6 binding peptide, and can be used for research of molecular imaging .

HY-D1419

mCP-BP-SFAC	Fluorescent Dye	Others
mCP-BP-SFAC is a luminogenic molecule. mCP-BP-SFAC exhibits strong sky-blue delayed fluorescence in neat films, with photoluminescence (PL) peaks at ~483 nm and delayed fluorescence lifetimes of 5.4 to 5.7 μs .

HY-D1420

TCP-BP-SFAC	Fluorescent Dye	Others
TCP-BP-SFAC is a luminogenic molecule. TCP-BP-SFAC exhibits strong sky-blue delayed fluorescence in neat films, with photoluminescence (PL) peaks at ~483 nm and delayed fluorescence lifetimes of 5.4 to 5.7 μs .

HY-P6009A

Cys-αvβ6-BP TFA

Integrin Cancer

Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide .

Cys-αvβ6-BP TFA	Integrin	Cancer
Cys-αvβ6-BP TFA is a cysteine-terminated αvβ6 binding peptide .

HY-115997

PROTAC HSP90 degrader BP3	PROTACs HSP	Cancer
PROTAC HSP90 degrader BP3 is a potent and selective degradation of HSP90 in a CRBN-dependent fashion. PROTAC HSP90 degrader BP3 has a certain degradation effect on HSP90 protein in MCF-7 cells (DC₅₀=0.99 μM). PROTAC HSP90 degrader BP3 inhibits the growth of breast cancer cell . PROTAC HSP90 degrader BP3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-U00035

MGB-BP-3

Bacterial Infection

MGB-BP-3 is an antibiotic that has been shown to be active against a broad range of important multi-resistant Gram-positive pathogens.

MGB-BP-3	Bacterial	Infection
MGB-BP-3 is an antibiotic that has been shown to be active against a broad range of important multi-resistant Gram-positive pathogens.

HY-RS00101

ABI3BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ABI3BP Human Pre-designed siRNA Set A contains three designed siRNAs for ABI3BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ABI3BP Human Pre-designed siRNA Set A ABI3BP Human Pre-designed siRNA Set A

HY-RS00986

ARL2BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ARL2BP Human Pre-designed siRNA Set A contains three designed siRNAs for ARL2BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ARL2BP Human Pre-designed siRNA Set A ARL2BP Human Pre-designed siRNA Set A

HY-RS14095

SYNJ2BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SYNJ2BP Human Pre-designed siRNA Set A contains three designed siRNAs for SYNJ2BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SYNJ2BP Human Pre-designed siRNA Set A SYNJ2BP Human Pre-designed siRNA Set A

HY-RS06410

HSF2BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HSF2BP Human Pre-designed siRNA Set A contains three designed siRNAs for HSF2BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HSF2BP Human Pre-designed siRNA Set A HSF2BP Human Pre-designed siRNA Set A

HY-RS06709

IL18BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IL18BP Human Pre-designed siRNA Set A contains three designed siRNAs for IL18BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IL18BP Human Pre-designed siRNA Set A IL18BP Human Pre-designed siRNA Set A

HY-RS06967

ITGB3BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ITGB3BP Human Pre-designed siRNA Set A contains three designed siRNAs for ITGB3BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ITGB3BP Human Pre-designed siRNA Set A ITGB3BP Human Pre-designed siRNA Set A

HY-RS12441

SAP30BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SAP30BP Human Pre-designed siRNA Set A contains three designed siRNAs for SAP30BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SAP30BP Human Pre-designed siRNA Set A SAP30BP Human Pre-designed siRNA Set A

HY-RS01619

BRI3BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
BRI3BP Human Pre-designed siRNA Set A contains three designed siRNAs for BRI3BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

BRI3BP Human Pre-designed siRNA Set A BRI3BP Human Pre-designed siRNA Set A

HY-RS07605

LGALS3BP Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LGALS3BP Human Pre-designed siRNA Set A contains three designed siRNAs for LGALS3BP gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LGALS3BP Human Pre-designed siRNA Set A LGALS3BP Human Pre-designed siRNA Set A

HY-RS02225

CD2BP2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CD2BP2 Human Pre-designed siRNA Set A contains three designed siRNAs for CD2BP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CD2BP2 Human Pre-designed siRNA Set A CD2BP2 Human Pre-designed siRNA Set A

HY-RS06332

HP1BP3 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
HP1BP3 Human Pre-designed siRNA Set A contains three designed siRNAs for HP1BP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HP1BP3 Human Pre-designed siRNA Set A HP1BP3 Human Pre-designed siRNA Set A

HY-RS04129

EBNA1BP2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
EBNA1BP2 Human Pre-designed siRNA Set A contains three designed siRNAs for EBNA1BP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

EBNA1BP2 Human Pre-designed siRNA Set A EBNA1BP2 Human Pre-designed siRNA Set A

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0848

Epibrassinolide 10+ Cited Publications 24-Epibrassinolide; B1105; BP55	Structural Classification Natural Products Classification of Application Fields Source classification Plants Biological Pesticide Research Agricultural Research Brassinolide Phytohormone Brassicaceae Brassica campestris L. Disease Research Fields Cancer	Apoptosis
Epibrassinolide (24-Epibrassinolide) is a ubiquitously occurring plant growth hormone which shows great potential to alleviate heavy metals and pesticide stress in plants . Epibrassinolide is a potential apoptotic inducer in various cancer cells without affecting the non-tumor cell growth .

HY-N0252

Catharanthine (+)-3,4-Didehydrocoronaridine	Cardiovascular Disease Apocynaceae Alkaloids Structural Classification Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don	Calcium Channel
Catharanthine ((+)-3,4-Didehydrocoronaridine), a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca ²⁺ channel (VOCC). Catharanthine has IC₅₀s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine lowers blood pressure (BP), heart rate (HR). Catharanthine has anti-cancer activity .

HY-N0252A

Catharanthine Tartrate (+)-3,4-Didehydrocoronaridine Tartrate	Cardiovascular Disease Apocynaceae Alkaloids Structural Classification Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Cancer Catharanthus roseus (L.) G. Don	Calcium Channel
Catharanthine ((+)-3,4-Didehydrocoronaridine) Tartrate, a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca ²⁺ channel (VOCC). Catharanthine Tartrate has IC₅₀s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine Tartrate lowers blood pressure (BP), heart rate (HR). Catharanthine Tartrate has anti-cancer activity .

HY-P1974

FR 901379 WF11899A	Structural Classification Microorganisms Antibiotics Source classification Other Antibiotics	Antibiotic
FR901379 (WF11899A) is a novel echinocandin-type lipopeptide antibiotic. FR901379 is primarily produced by mutant strain M-7 of Coleophoma empetri F-11899 (FERM BP-2635) .

HY-N0252B

Catharanthine Sulfate (+)-3,4-Didehydrocoronaridine Sulfate	Cardiovascular Disease Apocynaceae Alkaloids Structural Classification Classification of Application Fields Source classification Plants Disease Research Fields Indole Alkaloids Catharanthus roseus (L.) G. Don	Calcium Channel
Catharanthine ((+)-3,4-Didehydrocoronaridine) Sulfate, a constituent of anticancer vinca alkaloids, inhibits voltage-operated L-type Ca ²⁺ channel (VOCC). Catharanthine Sulfate has IC₅₀s of 220 μM and 8 μM for VOCC currents in cardiomyocytes and vascular smooth muscle cells (VSMCs), respectively. Catharanthine Sulfate lowers blood pressure (BP), heart rate (HR). Catharanthine Sulfate has anti-cancer activity .

HY-N6954

Garcinone C 1 Publications Verification	Structural Classification other families Xanthones Classification of Application Fields Garcinia oblongifolia Champ. ex Benth. Source classification Guttiferae Phenols Polyphenols Plants Disease Research Fields Cancer	ATM/ATR STAT CDK
Garcinone C, a xanthone derivative, is a natural compound extracted from Garcinia oblongifolia that is used as an anti-inflammatory, astringency and granulation-promoting medicine, and has potential cytotoxic effects on certain cancers. Garcinone C stimulates the expression levels of ATR and *4E-BP1, while efficiently inhibiting the expression levels of cyclin B1, cyclin D1, cyclin E2, cdc2, Stat3* and CDK7. Garcinone C significantly inhibits cell viability of the human Nasopharyngeal carcinoma (NPC) cell lines CNE1, CNE2, HK1 and HONE1 in a time‑ and dose‑dependent manner .

Cat. No.	Product Name	Chemical Structure

HY-17401S

Ranolazine-d8 dihydrochloride

Ranolazine-d₈ (dihydrochloride) is the deuterium labeled Ranolazine dihydrochloride. Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

HY-B0280S2

Ranolazine-d3
Ranolazine-d₃ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S1

Ranolazine-d8
Ranolazine-d₈ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina agent that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-B0280S

Ranolazine-d5
Ranolazine-d₅ is the deuterium labeled Ranolazine. Ranolazine (CVT 303) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine is also a partial fatty acid oxidation (FAO) inhibitor[3]. Antianginal agent.

HY-13777S

Zoledronic acid-d5
Zoledronic acid-d₅ is deuterated labeled Zoledronic Acid (HY-13777). Zoledronic Acid (Zoledronate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic Acid inhibits the differentiation and apoptosis of osteoclasts. Zoledronic Acid also has anti-cancer effects .

HY-B0309S2

Felodipine-d3
Felodipine-d₃ is the deuterium labeled Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier[1][2][3].

HY-B0309S1

Felodipine-d5
Felodipine-d₅ is deuterium labeled Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier[1][2][3].

HY-132670S

(R)-(-)-Felodipine-d5

(R)-(-)-Felodipine-d₅ is the deuterium labeled (R)-(-)-Felodipine. (R)-(-)-Felodipine is the S enantiomer of Felodipine. Felodipine, a dihydropyridine, is a potent, vasoselective calcium channel antagonist. Felodipine lowers blood pressure (BP) by selective action on vascular smooth muscle, especially in the resistance vessels. Felodipine, an anti-hypertensive agent, induces autophagy. Felodipine can cross the blood-brain barrier[1][2][3].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks